ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1107

Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): A Prospective Study

Xinlei Ma, Fan Yang, Jin Lin and Weiqian Chen, Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, China

Meeting: ACR Convergence 2022

Keywords: Autoinflammatory diseases, C-reactive protein (CRP), Inflammation, Polymyalgia Rheumatica (PMR), Therapy, alternative

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Miscellaneous Rheumatic and Inflammatory Diseases II

Session Type: Abstract Session

Session Time: 10:30AM-12:00PM

Background/Purpose: Polymyalgia Rheumatica (PMR) is a common inflammatory disease in elderly persons whose pathogenesis is unclear. Glucocorticoids are the first-line drugs for patients with PMR, but resulting in numerous side effects. As JAK kinase contributes to the inflammatory response, we explore whether JAK-inhibitor tofacitinib can treat patients with PMR.

We aimed to explore the pathogenetic features of PMR. We assessed the efficacy and safety of tofacitinib in patients with PMR (ChiCTR2000038253).

Methods: The gene expression profiles were analyzed in peripheral blood mononuclear cells (PBMCs) in patients with newly diagnosed PMR and sex-matched healthy controls (HC) by RNA sequencing and were confirmed by RT-PCR.

Patients with newly diagnosed PMR were randomized to tofacitinib (5mg bid) group and Glucocorticoids (Pred 15mg/day, gradually tapered) group. All PMR patients underwent clinical and laboratory examinations at 0, 4, 8, 12, 16, 20, and 24 weeks, and PMR activity disease scores (PMR-AS) were also calculated. The primary endpoint was the proportion of patients with PMR-AS≤10 at weeks 12 and 24. Secondary endpoints: PMR-AS score, CRP, and ESR at weeks 12 and 24.

Results: The gene expressions of PBMCs in 11 patients with newly diagnosed PMR were significantly different from those in 20 HC by RNA sequencing (Figure 1A). GO and KEGG analysis demonstrated that inflammatory response and cytokine-cytokine receptor interaction were the most remarkable pathways (data not shown). There were markedly expanded IL6R, IL1B, IL1R1, JAK2, TLR2, TLR4, TLR8, CCR1, CR1, S100A8, S100A12, and IL17RA expressions (Figure 1B, C). Those genes may trigger the JAK signaling.

27 patients with newly diagnosed PMR received the tofacitinib and 25 patients received glucocorticoid. No significant difference in gender ratio and age was found between the two groups. The baseline of PMR-AS was comparable in tofacitinib (19.02±5.98) and glucocorticoid group (21.38±5.52). At weeks 12 and 24, all patients in both groups had PMR-AS< 10. PMR-AS, CRP, and ESR were all significantly decreased at weeks 12, and 24 in both groups (Figure 2).

Only one patient in tofacitinib group did not respond well after 12 weeks, and one patient in glucocorticoid group did not respond well after 16 weeks. One patient had a mild urinary infection after 4 weeks treatment of tofacitinib, and recovered quickly to antibiotic without treatment interruption of tofacitinib. One patient had an increased blood pressure after 2 weeks treatment of glucocorticoid, falling back to normal level after additional antihypertensive therapy.

Conclusion: Many inflammatory genes associated with JAK signaling were increased in patients with PMR, suggesting an important role of JAK signaling in the development of PMR disease. We found that tofacitinib effectively treats patients with PMR as glucocorticoid does. No severe side effects were found in 24 weeks period treatment of tofacitinib.

Supporting image 1

Fig 1

Supporting image 2

Fig 2


Disclosures: X. Ma, None; F. Yang, None; J. Lin, None; W. Chen, None.

To cite this abstract in AMA style:

Ma X, Yang F, Lin J, Chen W. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): A Prospective Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/efficacy-and-safety-of-tofacitinib-in-patients-with-polymyalgia-rheumatica-east-pmr-a-prospective-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-tofacitinib-in-patients-with-polymyalgia-rheumatica-east-pmr-a-prospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology